语言选择
"Nanjing's innovation and entrepreneurship atmosphere is very strong, the relevant policies are more systematic and in place, the support of government departments at all levels is also in place, and the scientific research resources and industrial resources are very rich, which provides a good environment for scientific and technological research and development and the transformation of achievements. ” Liu Yongjun, executive vice president of , said that the institute will focus on cell therapy drugs and long-acting protein drugs, firmly go on the road of R&D and transformation of biological innovative drugs, and use technology to serve the society and health.
In the first quarter of this year, the finals of the 2022 National Disruptive Technology Innovation Competition came to an end, and the project of , a highlevel new R&D institution in Jiangning High-tech Zone, stood out from more than 2,800 entries across the country and won the winning award. “In 2018, the team took a fancy to Nanjing's favorable policy and entrepreneurial environment, and aimed at the research and development of high-quality new biological drug products around the world. Liu Yongjun, executive vice president of the institute, said that the company has been committed to promoting the transformation of scientific and technological achievements, and the award-winning project has started clinical research in the People's Hospital Affiliated to Wuhan University, providing a new treatment method for patients with advanced tumors.
On the morning of April 11, 2023, the Jiangsu Provincial Enterprise Development Strategy Research Association was led by Tao Zhiqiang, President of the Jiangsu Provincial Enterprise Development Strategy Research Association, to visit , and the participants learned in detail that Jiangsu Elliott Pharmaceutical Research Institute is a life science and technology platform and a high-tech company engaged in the research and development of cell therapy technology, focusing on the research and development of stem cells, immune cells, and a.IC cell therapy technology, and cooperating with well-known tertiary hospitals to carry out clinical research.
Liu Yongjun, executive vice president of , said: The general secretary mentioned the importance of scientific and technological innovation, and on the other hand, he also emphasized the main position of our enterprise.
On February 24, in the 2022 National Disruptive Technology Innovation Competition, the project "R&D and Industrialization of TCR Fusion CAR Cell Therapy Technology for Tumor Microenvironment Target E" of stood out from more than 2,800 entries across the country and won the winning award.